A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations
A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations
Myelofibrosis patients with high molecular risk mutations have an intrinsically aggressive disease with increased risk of leukemic transformation and reduced overall survival. As there are no therapies currently established in the subset of high molecular risk patients with early myelofibrosis, the study aimed to evaluate ruxolitinib in this patient population.
Inclusion Criteria:
Exclusion Criteria:
Concord NSW, New South Wales 2139, Australia
Wooloongabba, Queensland 4102, Australia
Halle S, 06120, Germany
Zrifin, 70300, Israel
Bunkyo Ku, Tokyo 113-8431, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Loerenskog, NO 1478, Norway
Putzu City, Chiayi Hsien 61363, Taiwan
Talas / Kayseri, 38039, Turkey (Türkiye)
Westbruy on Trym, Bristol BS10 5NB, United Kingdom